Precision BioSciences’ (DTIL) Buy Rating Reiterated at HC Wainwright

Precision BioSciences (NASDAQ:DTIL)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $60.00 price objective on the stock.

Other equities research analysts also recently issued reports about the company. Weiss Ratings raised Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Wall Street Zen raised Precision BioSciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Jefferies Financial Group reaffirmed a “buy” rating and set a $19.00 price target on shares of Precision BioSciences in a research report on Friday, March 13th. Finally, JonesTrading reaffirmed a “buy” rating and set a $30.00 price target on shares of Precision BioSciences in a research report on Friday, April 17th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.33.

Precision BioSciences Stock Performance

DTIL stock traded up $0.19 during midday trading on Wednesday, reaching $7.77. The stock had a trading volume of 598,250 shares, compared to its average volume of 259,598. The stock has a market cap of $200.48 million, a PE ratio of -2.12 and a beta of 1.31. The company has a debt-to-equity ratio of 0.29, a quick ratio of 14.02 and a current ratio of 14.02. The firm has a fifty day simple moving average of $6.97 and a two-hundred day simple moving average of $5.39. Precision BioSciences has a 52-week low of $3.53 and a 52-week high of $8.82.

Precision BioSciences (NASDAQ:DTIL) last issued its earnings results on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). The firm had revenue of $10.84 million during the quarter, compared to analysts’ expectations of $4.05 million. Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%. As a group, equities research analysts anticipate that Precision BioSciences will post -1.17 EPS for the current year.

Institutional Investors Weigh In On Precision BioSciences

Several institutional investors have recently bought and sold shares of the company. Bank of America Corp DE boosted its holdings in Precision BioSciences by 167.6% in the 1st quarter. Bank of America Corp DE now owns 27,416 shares of the company’s stock worth $151,000 after buying an additional 17,172 shares during the last quarter. Quantinno Capital Management LP purchased a new position in Precision BioSciences in the 1st quarter worth approximately $104,000. Octagon Capital Advisors LP lifted its stake in Precision BioSciences by 16.6% in the 1st quarter. Octagon Capital Advisors LP now owns 2,236,732 shares of the company’s stock worth $12,302,000 after purchasing an additional 318,737 shares in the last quarter. Affinity Asset Advisors LLC purchased a new position in Precision BioSciences in the 1st quarter worth approximately $3,289,000. Finally, XTX Topco Ltd purchased a new position in Precision BioSciences in the 4th quarter worth approximately $149,000. 37.99% of the stock is currently owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.